While this trial was in progress, Study ADP-0044-001 (NCT03132922) targeting the MAGE-A4 antigen with ADP-A2M4 commenced and significant responses were seen in patients with non-small cell lung cancer, head and neck cancer, and synovial sarcoma (13). Here, MAGEA4 is linked to head and neck cancer.